Article | December 20, 2023

Getting CMC Right For Emerging Technologies

Source: Cytiva
Regulatory network digital EHR EMR patient data GettyImages-1298626492

Establishing a chemistry, manufacturing, and controls (CMC) strategy that proves a clinical program is tightly controlled and can address risk is critical to avoiding the pitfalls that stall many promising therapeutics. This is often a herculean effort. Defining the manufacturing processes and product specifications that will help ensure product safety, quality, and consistency necessitates a complex, intensive evaluation that evolves as a program scales.

Shabbir Anik, Ph.D., has amassed decades of experience supporting new drug applications (NDAs) and investigational new drug (IND) filings at companies like Sutro Biopharma, Onyx Pharmaceuticals, Patheon, and Althea Group. This broad background has afforded Dr. Anik a wealth of expertise on executing a successful IND or NDA, avoiding clinical holds, and ultimately achieving regulatory approval. In an episode of The Business of Biotech podcast, Dr. Anik sat down to discuss how companies can develop a CMC strategy that balances near-term financial and logistical considerations with long-term regulatory and commercial goals.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Pharmaceutical Online